miR-365 inhibits the progression of gallbladder carcinoma and predicts the prognosis of Gallbladder carcinoma patients

References

• Zhu AX, Hong TS, Hezel AF, et al. Current management of gallbladder carcinoma. Oncologist. 2010;15(2):168–181.
   PubMed Web of Science ®Google Scholar
• Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.
   PubMed Web of Science ®Google Scholar
• Lazcano-Ponce EC, Miquel JF, Munoz N, et al. Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin. 2001;51(6):349–364.
   PubMed Web of Science ®Google Scholar
• Wistuba II, Gazdar AF. Gallbladder cancer: lessons from a rare tumour. Nat Rev Cancer. 2004;4(9):695–706.
   PubMed Web of Science ®Google Scholar
• Butte JM, Matsuo K, Gönen M, et al. Gallbladder cancer: differences in presentation, surgical treatment, and survival in patients treated at centers in three countries. J Am Coll Surg. 2011;212(1):50–61.
   PubMed Web of Science ®Google Scholar
• Li M, Zhang Z, Li X, et al. Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway. Nat Genet. 2014;46(8):872–876.
   PubMed Web of Science ®Google Scholar
• Bayoumi AS, Sayed A, Broskova Z, et al. Crosstalk between long noncoding RNAs and MicroRNAs in health and disease. Int J Mol Sci. 2016;17(3):356.
   PubMed Web of Science ®Google Scholar
• Parimon T, Brauer R, Schlesinger SY, et al. Syndecan-1 controls lung tumorigenesis by regulating microRNAs packaged in exosomes. Am J Pathol. 2018;188:1094–1103.
   PubMed Web of Science ®Google Scholar
• Li L, Tang J, Zhang B, et al. Epigenetic modification of MiR-429 promotes liver tumour-initiating cell properties by targeting Rb binding protein 4. Gut. 2015;64(1):156–167.
   PubMed Web of Science ®Google Scholar
• Cha SY, Choi YH, Hwang S, et al. Clinical impact of microRNAs associated with cancer stem cells as a prognostic factor in ovarian carcinoma. J Cancer. 2017;8(17):3538–3547.
   PubMed Web of Science ®Google Scholar
• Chen PS, Su JL, Hung MC. Dysregulation of microRNAs in cancer. J Biomed Sci. 2012;19:90.
   PubMed Web of Science ®Google Scholar
• Long M, Zhan M, Xu S, et al. miR-92b-3p acts as a tumor suppressor by targeting Gabra3 in pancreatic cancer. Mol Cancer. 2017;16(1):167.
   PubMedGoogle Scholar
• DeSano JT, Xu L. MicroRNA regulation of cancer stem cells and therapeutic implications. Aaps J. 2009;11(4):682–692.
   PubMed Web of Science ®Google Scholar
• Bao B, Azmi A, Li Y, et al. Targeting CSCs in tumor microenvironment: the potential role of ROS-associated miRNAs in tumor aggressiveness. Curr Stem Cell Res Ther. 2014;9(1):22–35.
   PubMed Web of Science ®Google Scholar
• Chen Z, Huang Z, Ye Q, et al. Prognostic significance and anti-proliferation effect of microRNA-365 in hepatocellular carcinoma. Int J Clin Exp Pathol. 2015;8(2):1705–1711.
   PubMed Web of Science ®Google Scholar
• Guo SL, Ye H, Teng Y, et al. Akt-p53-miR-365-cyclin D1/cdc25A axis contributes to gastric tumorigenesis induced by PTEN deficiency. Nat Commun. 2013;4:2544.
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhang G, Li H, et al. Serum microRNA-365 in combination with its target gene TTF-1 as a non-invasive prognostic marker for non-small cell lung cancer. Biomed Pharmacother. 2015;75:185–190.
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhang W, Liu S, et al. miR-365 targets ADAM10 and suppresses the cell growth and metastasis of hepatocellular carcinoma. Oncol Rep. 2017;37(3):1857–1864.
   PubMed Web of Science ®Google Scholar
• Li XF, Chen C, Xiang D-M, et al. Chronic inflammation-elicited liver progenitor cell conversion to liver cancer stem cell with clinical significance. Hepatology. 2017;66:1934–1951.
   Web of Science ®Google Scholar
• Xiang D, Cheng Z, Liu H, et al. Shp2 promotes liver cancer stem cell expansion by augmenting beta-catenin signaling and predicts chemotherapeutic response of patients. Hepatology. 2017;65(5):1566–1580.
   PubMed Web of Science ®Google Scholar
• Sharma KL, Yadav A, Gupta A, et al. Association of genetic variants of cancer stem cell gene CD44 haplotypes with gallbladder cancer susceptibility in North Indian population. Tumour Biol. 2014;35(3):2583–2589.
   PubMedGoogle Scholar
• Ma S, Lee TK, Zheng B-J, et al. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene. 2008;27(12):1749–1758.
   PubMed Web of Science ®Google Scholar
• Yamashita T, Ji J, Budhu A, et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology. 2009;136(3):1012–1024.
   PubMed Web of Science ®Google Scholar
• Shi CJ, Gao J, Wang M, et al. CD133(+) gallbladder carcinoma cells exhibit self-renewal ability and tumorigenicity. World J Gastroenterol. 2011;17(24):2965–2971.
   PubMed Web of Science ®Google Scholar
• Jin K, Xiang Y, Tang J, et al. miR-34 is associated with poor prognosis of patients with gallbladder cancer through regulating telomere length in tumor stem cells. Tumour Biol. 2014;35(2):1503–1510.
   PubMedGoogle Scholar
• Xiang DM, Sun W, Ning BF, et al. The HLF/IL-6/STAT3 feedforward circuit drives hepatic stellate cell activation to promote liver fibrosis. Gut. 2018 Sep;67(9):1704–1715
   Google Scholar
• Wu K, Ding J, Chen C, et al. Hepatic transforming growth factor beta gives rise to tumor-initiating cells and promotes liver cancer development. Hepatology. 2012;56(6):2255–2267.
   PubMed Web of Science ®Google Scholar
• Sun X, Xu C, Xiao G, et al. Breast cancer stem-like cells are sensitized to tamoxifen induction of self-renewal inhibition with enforced Let-7c dependent on Wnt blocking. Int J Mol Med. 2018. DOI:10.3892/ijmm.2018.3388.
   Web of Science ®Google Scholar
• Montalvo-Ortiz BL, Castillo-Pichardo L, Hernández E, et al. Characterization of EHop-016, novel small molecule inhibitor of Rac GTPase. J Biol Chem. 2012;287(16):13228–13238.
   PubMed Web of Science ®Google Scholar
• Zhao S, Cao Y, Liu S-B, et al. The E545K mutation of PIK3CA promotes gallbladder carcinoma progression through enhanced binding to EGFR. J Exp Clin Cancer Res. 2016;35(1):97.
   PubMedGoogle Scholar
• Caldow Pilgrim CH, Groeschl RT, Quebbeman EJ, et al. Recent advances in systemic therapies and radiotherapy for gallbladder cancer. Surg Oncol. 2013;22(1):61–67.
   PubMed Web of Science ®Google Scholar
• Xie F, Xu X, Xu A, et al. Aberrant activation of Sonic hedgehog signaling in chronic cholecystitis and gallbladder carcinoma. Hum Pathol. 2014;45(3):513–521.
   PubMed Web of Science ®Google Scholar
• Lim LP, Lau NC, Garrett-Engele P, et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature. 2005;433(7027):769–773.
   PubMed Web of Science ®Google Scholar
• Xu Y, Chu H, Zhou Y, et al. miR-365 functions as a tumor suppressor by directly targeting CYR61 in osteosarcoma. Biomed Pharmacother. 2017;98:531–537.
   PubMed Web of Science ®Google Scholar
• Xiao Y, Lin M, Jiang X, et al. The recent advances on liver cancer stem cells: biomarkers, separation, and therapy. Anal Cell Pathol (Amst). 2017;2017:5108653.
   PubMedGoogle Scholar
• Wang X, Sun W, Shen W, et al. Long non-coding RNA DILC regulates liver cancer stem cells via IL-6/STAT3 axis. J Hepatol. 2016;64(6):1283–1294.
   PubMed Web of Science ®Google Scholar
• Tharmapalan P, Mahendralingam M, Berman HK, et al. Mammary stem cells and progenitors: targeting the roots of breast cancer for prevention. Embo J. 2019;38(14):e100852.
   PubMed Web of Science ®Google Scholar
• Su R, Dong L, Li Y, et al. Targeting FTO suppresses cancer stem cell maintenance and immune evasion. Cancer Cell. 2020;38(1):79–96 e11.
   PubMed Web of Science ®Google Scholar
• Bekaii-Saab T, El-Rayes B. Identifying and targeting cancer stem cells in the treatment of gastric cancer. Cancer. 2017;123(8):1303–1312.
   PubMed Web of Science ®Google Scholar
• Li XX, Wang J, Wang H-L, et al. Characterization of cancer stem-like cells derived from a side population of a human gallbladder carcinoma cell line, SGC-996. Biochem Biophys Res Commun. 2012;419(4):728–734.
   PubMed Web of Science ®Google Scholar
• Li S, Yan T, Deng R, et al. Low dose of kaempferol suppresses the migration and invasion of triple-negative breast cancer cells by downregulating the activities of RhoA and Rac1. Onco Targets Ther. 2017;10:4809–4819.
   PubMed Web of Science ®Google Scholar
• Araiza-Olivera D, Feng Y, Semenova G, et al. Suppression of RAC1-driven malignant melanoma by group A PAK inhibitors. Oncogene. 2017;37:944–952.
   PubMed Web of Science ®Google Scholar
• Humphries-Bickley T, Castillo-Pichardo L, Corujo-Carro F, et al. Pharmacokinetics of Rac inhibitor EHop-016 in mice by ultra-performance liquid chromatography tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2015;981–982:19–26.
   PubMed Web of Science ®Google Scholar